PHARMACOLOGY Drotrecogin alfa (activated) is a recombinant human activated protein C (9).
What does rhAPC stand for?
rhAPC stands for Recombinant Human Activated Protein C
This definition appears frequently and is found in the following Acronym Finder categories:
- Science, medicine, engineering, etc.
See other definitions of rhAPC
- Reproductive Health Advocacy Network
- Rural Healthy Aging Network (West Virginia University; Morgantown, WV)
- Rental Housing Association of Northern Alameda County
- Reining Horse Association of the Northwest
- Radiation Hardened Applications Program
- Red Hat Accredited Professional (Red Hat, Inc.)
- Refugee Health Assessment Program (California and Massachusetts)
- Regional Haze Action Plan (Association of Southeast Asian Nations)
- Regional HIV/AIDS Program (Pretoria, South Africa; USAID)
- Residential Historical Abuse Program (Canada)
- Rental Housing Association of Pierce County (Lakewood, WA)
- Rental Housing Association of Puget Sound (Seattle, WA)
- Rode Hard and Put Up Wet
- Rabbit Heart Acetohexamide Reductase
- Recombinant Human Androgen Receptor (cellular physiology)
- Reducing Heart Attack Risk
- Radiative Heating and Afterbody Radiometry Experiments (NASA)
- Red Hat Advanced Server
- Red Hat Application Stack (software)
- Resonance Health Analysis Services Pty. Ltd. (Perth, Western Australia, Australia)
Samples in periodicals archive:
This press release is transmitted on behalf of Eli Lilly and Company Indiamapolis - Eli Lilly and Company (NYSE: LLY) announced today that it is stopping enrollment in a Phase III clinical trial investigating the therapeutic potential of recombinant human activated protein C in the treatment of severe sepsis.
Three natural anticoagulants have been tested in large phase III trials in sepsis: recombinant human activated Protein C, tissue factor pathway inhibitor and antithrombin.
The CPMP, comprised of regulators from 15-member countries, based its positive opinion on the results of an international Phase III clinical trial (known as PROWESS, Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis), which were published March 8, 2001 in The New England Journal of Medicine.
The approval was based on the results of a landmark, international Phase III clinical trial (known as PROWESS, Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis), which were published March 8, 2001, in New England Journal of Medicine.